Novel Parkinson’s Therapy Moves Ahead Through Korea Deal
This article was originally published in PharmAsia News
South Korean researchers have taken a step forward in developing a disease-modifying treatment for Parkinson's disease. Kainos Medicine has licensed in an innovative candidate for the now incurable disease, KR-33493, which is set for clinical trials in the country and is expected to be a first-in-class drug that can curb dopaminergic neuronal cell death.
You may also be interested in...
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.